Carafate (Sucralfate) Patent Expiration, LOE Window & CMS Spending

Carafate (Sucralfate) by AbbVie: Off-Patent Genericized (AB Competition), 12 AB generics, $9.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN018333 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$9.9M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$8.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.